Werewolf Therapeutics presented new clinical data for its cancer therapeutic candidates WTX-124 and WTX-330 at the SITC 2026 Annual Meeting, showing favorable safety profiles and antitumor activity in patients with highly advanced, treatment-refractory solid tumors.